Curis, Inc. (NASDAQ:CRIS) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d) Exhibits
99.1Press Release dated May22, 2018
CURIS INC ExhibitEX-99.1 2 d566725dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Curis Announces 1-for-5 Reverse Stock Split LEXINGTON,…To view the full exhibit click here
About Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.
